A phase 1/1b study of IAM1363 in participants with advanced cancers harboring HER2 alterations.

Disease:

HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer

Study phase:

Phase I

Physician name:

Ecaterina Ileana Dumbrava

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-632-6789